Please assess the completion status of the following clinical trial:

Trial Title: Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Recipient Inclusion criteria (within 28 days of this protocol's lymphodepleting conditioning regimen and after donor and recipient consent-signing)~2. Diagnosis of CD22+ acute lymphoblastic leukemia that is a. refractory to therapy or b. in second or greater relapse without other standard therapeutic options~3. Patient may have been the recipient of an allogeneic hematopoietic stem cell transplant; however; there must be no evidence of Graft-versus-host disease (GVHD)~4. Off prednisone or other immunosuppressive medications for at least 3 days prior to both the lymphodepleting regimen and the NK infusion~5. Zubrod performance scale \</= 2 or Lansky performance scale \>/= 60~6. Adequate renal function defined as: Serum creatinine (Cr), for adults \</= 2 mg/dL, for children \</= 2 mg/dL or \</= 2 times upper limit of normal (ULN) for age (whichever is less). If abnormal renal function, then Cr clearance \>/= 60 mL/min/1.73 m\^2~7. Adequate liver function defined as: Total bilirubin \</= 2 mg/dL and serum glutamic-pyruvic transaminase (SGPT)/ alanine transaminase(ALT) \</= 5 \* ULN for age (unless Gilbert's disease or abnormal liver function due to primary disease)~8. Pulmonary symptoms controlled by medication and pulse oximetry \>/= 92% room air~9. Negative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non childbearing is defined as greater than one year post-menopausal or surgically sterilized~10. Requirement of sexually active females and males to use any form of contraception considered effective and medically acceptable by the Investigator. \[Acceptable forms: birth control implants, birth control pills, a vasectomy (male surgical sterilization), or a double-barrier method (any 2 of the following in combination: intrauterine device (IUD), male or female condom with spermicidal gel, a diaphragm, a sponge, and/or cervical cap)\]~11. Negative serology for human immunodeficiency virus (HIV)~12. Donor must be related to recipient and is predicted to be alloreactive based upon the presence of the relevant KIR genes and incompatibility with the recipient for HLA C or Bw antigens~13. Donor must have infectious disease marker testing \[Hepatitis B, C, HIV, CMV, Syphilis (RPR), Chagas, HTLV, and West Nile Virus\] and CBC differential and platelet studies that meet standard medical eligibility criteria for allogeneic blood stem cell donation within 7 days of apheresis~14. Donor, if a female of childbearing potential (non-childbearing is defined as greater than one year post-menopause or surgically sterilized), must have a negative serum test to rule out pregnancy within 14 days of apheresis~15. Donor must meet standard medical eligibility criteria for allogeneic stem cell donation~Exclusion Criteria:~1. Exclusion criteria applies to both the initiation of conditioning regimen and to the NK infusion~2. Active central nervous system (CNS) leukemia~3. Active infection (defined as on antimicrobial therapy and or febrile)~4. Breast-feeding females~5. Currently using a ventilator or requiring supplemental oxygen~6. Currently undergoing dialysis~7. Currently using a Phase I, II, or III investigational agent. These agents should be stopped within 21 days of NK infusion~8. New detected cardiac arrhythmia not controlled with medical management within prior 72 hour period.~9. Hypotension requiring pressor support within prior 72 hour period~10. Uncontrolled infection defined as daily fever greater than or equal to 38.2°C within prior 24 hours and new positive culture for bacteria, fungus, or virus within 72 hours prior to NK -cell infusion, if clinically indicated~11. Taking corticosteroids by mouth or intravenously within prior 72 hour period~12. Ascites requiring paracentesis within prior 72 hour period. (If the patient requires paracentesis within 72 hours of NK cell infusion, they will not be eligible to receive the infusion.)~13. Seizure activity or clinically detectable encephalopathy or new focal neurologic deficits within prior 72 hour period~14. Donor has active infection (defined as on antimicrobial therapy and/or febrile) within 7 days of apheresis~15. Donor is pregnant female or breast-feeding female (within 7 days of apheresis)

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Haploidentical NK cells + Epratuzumab (Type: EXPERIMENTAL): Haploidentical donor-derived NK cell infusion, Epratuzumab 360 mg/m\^2 once a day by vein (IV) on Day -4, Day -1 and Days 3, 6, 10, 13 and 17, and low-dose interleukin-2 (IL-2) Subcutaneous injections three times a week for 9 doses on Days 0 to 21; Fludarabine 25 mg/m\^2 once a day IV on Day -6 through Day -2 over 30 minutes; Cyclophosphamide 60 mg/kg once a day IV on Days -5 and -4 over 2 hours. Mesna 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.

Based on this trial design, predict the completion outcome and termination type (if applicable).